Immunai nets $215m Series B

Immunai, a New York-based biotech company, has raised $215 million in Series B funding.

Immunai, a New York-based biotech company, has raised $215 million in Series B funding. Koch Disruptive Technologies led the round with participation from other backers that included Talos VC, 8VC, Alexandria Venture Investments, Piedmont and ICON.

Source: Press Release